• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Nanobiotix S.A.

    < Previous 1 2 Next >
    NANOBIOTIX to Participate in Multiple Investor Conferences in November
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    Voting Rights and Shares Capital of the Company
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    Voting Rights and Shares Capital of the Company
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    Voting Rights and Shares Capital of the Company
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    Voting Rights and Shares Capital of the Company
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    NANOBIOTIX to Present at the Jefferies Global Healthcare Conference
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    Voting Rights and Shares Capital of the Company
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    Voting Rights and Shares Capital of the Company
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    Nanobiotix to Present at Upcoming Investor Conferences in March
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    Voting Rights and Shares Capital of the Company
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    Voting Rights and Shares Capital of the Company
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    Voting Rights and Shares Capital of the Company
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update
    From Nanobiotix S.A.
    Via GlobeNewswire
    Tickers NBTX
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.